Biotech Values

[DewDiligence]

>…but not in a hospital setting were the patients are admitted already.<

Thanks—that’s the point I should have made in the prior thread about the reluctance of hospitals to pay a premium price for improvements in “convenience.”

Selling a premium-priced drug to hospitals is a tough business to be in because hospitals are smart and poor (or think they are). A better business model is one that targets end-users who are rich and dumb, which is why so many companies are trying to get into aesthetic medicine.